XML 84 R72.htm IDEA: XBRL DOCUMENT v3.19.1
Commitments and Contingencies (Details Narrative) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Feb. 28, 2019
Apr. 30, 2017
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Dec. 31, 2017
Damages in lawsuit $ 640          
Accrued expenses     $ 800   $ 800  
Royalty payments     191 $ 183    
Stock based payments     $ 713 $ 751    
Business acquisition description     In consideration for the acquisition of the intellectual property rights, the Company is obligated to make payments to the Inventors based on the completion of certain milestones, generally consisting of: (1) a payment payable within 30 days after the issuance of the first patent in the United States arising from the acquired intellectual property (if any); (2) a payment payable within 30 days after the Company files the first investigational new drug application (“IND”) with the FDA for the first product arising from the acquired intellectual property (if any); (3) for certain of the Inventors, a payment payable within 30 days after the Company files the first new drug application with the FDA for the first product arising from the acquired intellectual property (if any); and (4) certain royalty payments based on the net receipts received by the Company in connection with the sale or licensing of any product based on the acquired intellectual property (if any), after deducting (among other things) the Company’s development costs associated with such product. If, following five years after the date of the applicable asset purchase agreement, the Company either (a) for certain of the Inventors, has not filed an IND or, for the remaining Inventors, has not initiated a study where data is derived, or (b) has failed to generate royalty payments to the Inventors for any product based on the acquired intellectual property, the Inventors may terminate the applicable asset purchase agreement and request that the Company re-assign the acquired technology to the Inventors.      
Maximum [Member]            
Damages in lawsuit $ 1,400          
Settlement Agreement [Member]            
Accrued expenses         640  
Klarity License Agreement [Member] | Richard L. Lindstrom, M.D [Member]            
Royalty payment description   The Company is required to make royalty payments to Dr. Lindstrom ranging from 3% - 6% of net sales, dependent upon the final formulation of the Klarity Product sold.        
License Agreement [Member] | Dr. Lindstrom [Member]            
Royalty payments     $ 22      
License Agreement [Member] | Initial Payment [Member] | Richard L. Lindstrom, M.D [Member]            
Royalty payments   $ 50        
Net sales   100        
License Agreement [Member] | Second Payment [Member] | Richard L. Lindstrom, M.D [Member]            
Royalty payments   50        
License Agreement [Member] | Final Payment [Member] | Richard L. Lindstrom, M.D [Member]            
Royalty payments   50 15      
Net sales   $ 50        
Sales and Marketing Agreements [Member]            
Stock based payments         $ 75  
Commission expense incurred     $ 542      
Sales and Marketing Agreements [Member] | Maximum [Member]            
Commission payments, percentage           14.00%
Sales and Marketing Agreements [Member] | Minimum [Member]            
Commission payments, percentage           10.00%